BRAF融合在非小细胞肺癌中的研究进展

In advanced non-small cell lung cancer (NSCLC), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation is highly malignant and has poor prognosis, and currently Dabrafenib in combination with Trametinib is approved for first-line treatment of patients with BRAF V600 mutation. In addition to...

Descripción completa

Detalles Bibliográficos
Autores principales: XIAO, Ping, ZHONG, Diansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663773/
https://www.ncbi.nlm.nih.gov/pubmed/37989341
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.28
_version_ 1785138473039036416
author XIAO, Ping
ZHONG, Diansheng
author_facet XIAO, Ping
ZHONG, Diansheng
author_sort XIAO, Ping
collection PubMed
description In advanced non-small cell lung cancer (NSCLC), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation is highly malignant and has poor prognosis, and currently Dabrafenib in combination with Trametinib is approved for first-line treatment of patients with BRAF V600 mutation. In addition to mutations, BRAF fusion can also occur. With the development of gene detection, the detection of BRAF fusion is gradually increasing, but there is a lack of effective therapeutic strategies for BRAF fusion. In this paper, we review the clinical characteristics, mechanism of action, and clinical treatment of BRAF fusion to provide a basis for the treatment of BRAF fusion in NSCLC patients.
format Online
Article
Text
id pubmed-10663773
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial board of Chinese Journal of Lung Cancer
record_format MEDLINE/PubMed
spelling pubmed-106637732023-10-20 BRAF融合在非小细胞肺癌中的研究进展 XIAO, Ping ZHONG, Diansheng Zhongguo Fei Ai Za Zhi Review In advanced non-small cell lung cancer (NSCLC), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation is highly malignant and has poor prognosis, and currently Dabrafenib in combination with Trametinib is approved for first-line treatment of patients with BRAF V600 mutation. In addition to mutations, BRAF fusion can also occur. With the development of gene detection, the detection of BRAF fusion is gradually increasing, but there is a lack of effective therapeutic strategies for BRAF fusion. In this paper, we review the clinical characteristics, mechanism of action, and clinical treatment of BRAF fusion to provide a basis for the treatment of BRAF fusion in NSCLC patients. Editorial board of Chinese Journal of Lung Cancer 2023-10-20 /pmc/articles/PMC10663773/ /pubmed/37989341 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.28 Text en 版权所有 © 2023《中国肺癌杂志》编辑部 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle Review
XIAO, Ping
ZHONG, Diansheng
BRAF融合在非小细胞肺癌中的研究进展
title BRAF融合在非小细胞肺癌中的研究进展
title_full BRAF融合在非小细胞肺癌中的研究进展
title_fullStr BRAF融合在非小细胞肺癌中的研究进展
title_full_unstemmed BRAF融合在非小细胞肺癌中的研究进展
title_short BRAF融合在非小细胞肺癌中的研究进展
title_sort braf融合在非小细胞肺癌中的研究进展
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663773/
https://www.ncbi.nlm.nih.gov/pubmed/37989341
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.28
work_keys_str_mv AT xiaoping brafrónghézàifēixiǎoxìbāofèiáizhōngdeyánjiūjìnzhǎn
AT zhongdiansheng brafrónghézàifēixiǎoxìbāofèiáizhōngdeyánjiūjìnzhǎn

Ejemplares similares